ClinicalTrials.gg
CompletedNCT06955598Updated Dec 15, 2025

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus

A Phase 1 interventional study of SHR-2173 in Systemic Lupus Erythematosus, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Nov 2024, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Enrollment
129th of 245
30 · median 36
Started
2024
with 42 others
Phase 1
109 of 266
85 open now
Registered
169th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 129th largest by enrollment of the 245 interventional ones that give a count, is one of 43 that started in 2024, is one of 109 in phase 1, and was the 169th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple subcutaneous injections of SHR-2173 in patients with systemic lupus erythematosus (SLE).

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-65 years, regardless of gender;
  2. Weight ≥45.0 kg at screening;
  3. Confirmed SLE diagnosis for ≥12 weeks at screening.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women, or those with a positive human chorionic gonadotropin (HCG) test.
  2. History of alcohol abuse or illegal drug use within one year prior to screening.
  3. Blood donation ≥450 mL within 8 weeks prior to screening or plans to donate blood during the study.
  4. Current active infection or a history of active tuberculosis
  5. Other inflammatory or diseases beyond SLE and LN that may interfere with the interpretation of trial results or clinical assessment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Treatment group A:

    SHR-2173 injection dose 1

    Drug: SHR-2173

  • Experimental
    Treatment group B:

    SHR-2173 injection dose 2

    Drug: SHR-2173

  • Experimental
    Treatment group C:

    SHR-2173 injection dose 3

    Drug: SHR-2173

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events

    Time frame: Week 0~16

Secondary outcomes

  1. Cmax,

    Time frame: Week 0~16

  2. AUC0-t,

    Time frame: Week 0~16

  3. Anti- SHR -2173 antibody (ADA)

    Time frame: Week 0~16

07

Study locations

1 site
  • Renji Hospital affiliated to Shanghai Jiaotong
    Shanghai, Shanghai Municipality 200000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Nov 2025, 11 months.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 11 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
May 2, 2025
StartActual
Nov 24, 2024
Primary completionActual
Nov 10, 2025
CompletionActual
Nov 21, 2025
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06955598
Responsible party
Sponsor
First posted
May 2, 2025
Start date
Nov 24, 2024
Primary completion
Nov 10, 2025
Completion
Nov 21, 2025
Last update
Dec 15, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-2173

Start the discussion